

## Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts

Ritsuko Masuyama, ... , Roger Bouillon, Geert Carmeliet

*J Clin Invest.* 2006;116(12):3150-3159. <https://doi.org/10.1172/JCI29463>.

Research Article

Bone biology

Genomic actions induced by  $1\alpha,25$ -dihydroxyvitamin  $D_3$  [ $1,25(OH)_2D_3$ ] are crucial for normal bone metabolism, mainly because they regulate active intestinal calcium transport. To evaluate whether the vitamin D receptor (VDR) has a specific role in growth-plate development and endochondral bone formation, we investigated mice with conditional inactivation of VDR in chondrocytes. Growth-plate chondrocyte development was not affected by the lack of VDR. Yet vascular invasion was impaired, and osteoclast number was reduced in juvenile mice, resulting in increased trabecular bone mass. In vitro experiments confirmed that VDR signaling in chondrocytes directly regulated osteoclastogenesis by inducing receptor activator of NF- $\kappa$ B ligand (RANKL) expression. Remarkably, mineral homeostasis was also affected in chondrocyte-specific *VDR*-null mice, as serum phosphate and  $1,25(OH)_2D$  levels were increased in young mice, in whom growth-plate activity is important. Both in vivo and in vitro analysis indicated that VDR inactivation in chondrocytes reduced the expression of FGF23 by osteoblasts and consequently led to increased renal expression of  $1\alpha$ -hydroxylase and of sodium phosphate cotransporter type IIa. Taken together, our findings provide evidence that VDR signaling in chondrocytes is required for timely osteoclast formation during bone development and for the endocrine action of bone in phosphate homeostasis.

Find the latest version:

<https://jci.me/29463/pdf>





# Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts

Ritsuko Masuyama,<sup>1</sup> Ingrid Stockmans,<sup>1</sup> Sophie Torrekens,<sup>1</sup> Riet Van Looveren,<sup>1</sup> Christa Maes,<sup>1</sup> Peter Carmeliet,<sup>2</sup> Roger Bouillon,<sup>1</sup> and Geert Carmeliet<sup>1</sup>

<sup>1</sup>Laboratory of Experimental Medicine and Endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium.

<sup>2</sup>Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium.

**Genomic actions induced by  $1\alpha,25$ -dihydroxyvitamin D<sub>3</sub> [ $1,25(\text{OH})_2\text{D}_3$ ] are crucial for normal bone metabolism, mainly because they regulate active intestinal calcium transport. To evaluate whether the vitamin D receptor (VDR) has a specific role in growth-plate development and endochondral bone formation, we investigated mice with conditional inactivation of VDR in chondrocytes. Growth-plate chondrocyte development was not affected by the lack of VDR. Yet vascular invasion was impaired, and osteoclast number was reduced in juvenile mice, resulting in increased trabecular bone mass. In vitro experiments confirmed that VDR signaling in chondrocytes directly regulated osteoclastogenesis by inducing receptor activator of NF- $\kappa$ B ligand (RANKL) expression. Remarkably, mineral homeostasis was also affected in chondrocyte-specific VDR-null mice, as serum phosphate and  $1,25(\text{OH})_2\text{D}_3$  levels were increased in young mice, in whom growth-plate activity is important. Both in vivo and in vitro analysis indicated that VDR inactivation in chondrocytes reduced the expression of FGF23 by osteoblasts and consequently led to increased renal expression of  $1\alpha$ -hydroxylase and of sodium phosphate cotransporter type IIa. Taken together, our findings provide evidence that VDR signaling in chondrocytes is required for timely osteoclast formation during bone development and for the endocrine action of bone in phosphate homeostasis.**

## Introduction

Vitamin D is the major regulator of calcium homeostasis and protects the organism from calcium deficiency via effects on the intestine, kidney, and bone. Vitamin D interacts with the vitamin D receptor (VDR), a transcription factor regulating gene expression in several cell types, including osteoblasts and chondrocytes. Disorders of the vitamin D endocrine system by mutations in or inactivation of the VDR (1–3) or the  $1\alpha$ -hydroxylase gene, CYP27B1 (4–6), result in profound disturbances of mineral homeostasis and of bone mineralization. Decreased active intestinal calcium absorption due to reduced expression of epithelial calcium channels (7) is a crucial mechanism contributing to the phenotype. The importance of calcium absorption is further evidenced by the fact that calcium supplementation rescued hypocalcemia and hyperparathyroidism and restored bone mineralization both in patients and mice with loss of VDR function (8, 9), which raises questions about the role of VDR in bone metabolism. However, these data do not exclude the possibility that VDR may have a specific, although not essential, role in bone. Accordingly, the ability of osteoblasts to support osteoclastogenesis is regulated by but not dependent on vitamin D signaling (10). In addition, in vitro studies revealed

that osteoblasts lacking VDR demonstrate enhanced differentiation potential (11) although transgenic overexpression of VDR in mature osteoblasts suggests that VDR exerts an anabolic function in bone (12). Finally, growth-plate abnormalities in mice lacking VDR were observed before the onset of hypocalcemia (3), suggesting a defined role for VDR in endochondral-bone formation.

The start of endochondral ossification is characterized by differentiation of aggregated mesenchymal cells into chondrocytes forming cartilage elements that later evolve to hypertrophic and finally terminal differentiated chondrocytes. The latter region is subsequently invaded by blood vessels accompanied by osteoclasts and osteoblasts, thereby replacing the cartilage with bone and bone marrow (13). Vitamin D signaling may regulate this process, as enhanced vascular invasion is observed when mice are treated with  $1\alpha,25$ -dihydroxyvitamin D<sub>3</sub> [ $1,25(\text{OH})_2\text{D}_3$ ], probably resulting from increased availability of VEGF (14).


Besides its role in calcium homeostasis, vitamin D also affects phosphate homeostasis by participating in a negative feedback loop with FGF23. The phosphaturic factor FGF23 is mainly produced by bone (15) and induces renal phosphate wasting by suppressing renal tubular sodium phosphate cotransporter type IIa (NPT2a) expression (16). Vitamin D enhances the production of FGF23, which in its turn suppresses renal CYP27B1 expression (16). Mice lacking VDR show decreased circulating FGF23 levels in agreement with the negative reciprocal regulation (17).

To elucidate the role of vitamin D genomic action during endochondral bone development under assumed normal mineral homeostasis, we generated mice lacking VDR specifically in chondrocytes. The inactivation of VDR in chondrocytes did not manifestly affect chondrocyte development. Yet trabecular bone volume (BV/TV) was increased in early life due to reduced osteoclast num-

**Nonstandard abbreviations used:** BMD, bone mineral density; BV/TV, trabecular bone volume; Col2, collagen 2a1; Col2Cre, Cre driven by collagen 2 promoter; *Cre-VDR<sup>fl/fl</sup>*, *Col2Cre<sup>-/-</sup>VDR<sup>fl/fl</sup>* (mice); HPRT, hypoxanthine-guanine phosphoribosyl transferase; NPT2a, sodium phosphate cotransporter type IIa;  $1,25(\text{OH})_2\text{D}_3$ ,  $1\alpha,25$ -dihydroxyvitamin D<sub>3</sub>; OPG, osteoprotegerin; PGE<sub>2</sub>, prostaglandin E<sub>2</sub>; PTH, parathyroid hormone; qRT-PCR, quantitative real-time PCR; RANKL, receptor activator of NF- $\kappa$ B ligand; Runx2, runt-related transcription factor 2; TRAP, tartrate-resistant acid phosphatase; VDR, vitamin D receptor; *VDR<sup>fl/fl</sup>*, floxed VDR (mice).

**Conflict of interest:** The authors have declared that no conflict of interest exists.

**Citation for this article:** *J. Clin. Invest.* 116:3150–3159 (2006). doi:10.1172/JCI29463.



**Figure 1** Inactivation of the *VDR* gene in chondrocytes. **(A)** Schematic representation of targeting construct *pNT vector/VDR*, the *VDR<sup>WT</sup>* allele, and the *VDR<sup>fl</sup>* allele after Cre excision of the floxed neo cassette and probe used for identifying correct Cre excision of floxed exon 2. Restriction sites are indicated. Ex, exon. **(B)** Southern blot of *SacI*-digested genomic DNA from *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* and *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice using internal probe. **(C)** *VDR* gene expression in growth-plate chondrocytes of *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* (*Cre<sup>-</sup>*) and *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* (*Cre<sup>+</sup>*) mice (*n* = 6) was assessed by qRT-PCR analysis and calculated as a ratio to the *HPRT* mRNA copies. *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* value was set at 100%. \*\**P* < 0.01 versus *Cre<sup>-</sup>VDR<sup>fl/fl</sup>*. **(D)** qRT-PCR analysis of *CYP24* mRNA levels in primary chondrocyte culture stimulated with vehicle (veh) or 1,25(OH)<sub>2</sub>D<sub>3</sub> (10<sup>-10</sup> M and 10<sup>-8</sup> M) for 48 hours and 72 hours. Values are corrected for *HPRT* mRNA copies and are shown as means ± SEM in log scale. \*\**P* < 0.01 versus vehicle.

ber. In vitro experiments confirmed that VDR signaling in chondrocytes directly regulates osteoclastogenesis by inducing receptor activator of NF-κB ligand (RANKL) expression. Unexpectedly, serum phosphate and 1,25(OH)<sub>2</sub>D levels were increased in these mice before weaning. Both in vivo and in vitro analysis showed that normal FGF23 production by osteoblasts is dependent on VDR genomic action in chondrocytes. Taken together, these results show that VDR signaling in chondrocytes is required for timely osteoclastogenesis during bone development and regulates FGF23 production by osteoblasts.

**Results**

*Loss of VDR in growth-plate chondrocytes does not affect their development.* To evaluate the contribution of VDR in early endochondral-bone development, floxed VDR (*VDR<sup>fl/fl</sup>*) mice were intercrossed with transgenic mice in which Cre recombinase was driven by collagen 2a1 (*Col2*) promoter (Figure 1A). The efficiency of chondrocyte-specific VDR inactivation was assessed at the DNA, RNA, and functional levels. Correct excision of the floxed *VDR* exon was demonstrated by Southern blot analysis of tail-extracted DNA from 15-day-old *Col2Cre<sup>+/-</sup>VDR<sup>fl/fl</sup>* mice (further defined as mutant *Cre<sup>+</sup>VDR<sup>fl/fl</sup>*), which was not observed in WT *Col2Cre<sup>-/-</sup>VDR<sup>fl/fl</sup>* (*Cre<sup>-</sup>VDR<sup>fl/fl</sup>*) mice. At this age, the tail vertebrae still contain collagen 2-expressing cells (Figure 1B). Analysis of *VDR* mRNA expression by quantitative real-time PCR (qRT-PCR) revealed undetectable *VDR* levels

in chondrocytes isolated from neonatal *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice whereas *VDR* was abundantly expressed in *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* chondrocytes (Figure 1C). This efficient VDR inactivation was confirmed by assessing 1,25(OH)<sub>2</sub>D<sub>3</sub>-induced gene transcription in cultured primary chondrocytes (Figure 1D). *CYP24* mRNA expression was strongly increased by 1,25(OH)<sub>2</sub>D<sub>3</sub> treatment (10<sup>-8</sup> M) in *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* chondrocytes, as anticipated, but not in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* chondrocytes. On the other hand, VDR activity and/or expression was not altered in cultured osteoblasts, kidney, or intestine (data not shown) of *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice.

*Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice were viable, showed normal growth curves during the examined period, and did not display any overt phenotype (data not shown). Longitudinal bone growth, assessed by measuring femur length, was similar between the 2 genotypes at all investigated ages, including E15.5, the neonatal period, 15 days (data not shown), and 8 weeks (Table 1). To determine whether VDR inactivation affects chondrocyte development, growth-plate morphology and gene expression were analyzed. No gross morphological changes, assessed on toluidine blue-stained sections of the tibiae, were noticed at any age in cartilage of *Cre<sup>+</sup>VDR<sup>fl/fl</sup>*

mice (Figure 2, C and D; only histology of 15-day-old mice is shown.). The total length of the growth plate (data not shown) as well as the length of hypertrophic cartilage in tibiae of neonatal and 15-day-old mice were similar between the 2 genotypes (Figure 2E). Also, the amount of growth-plate mineralization in 8-week-old mice did not differ (Table 1). The mRNA level of *Col2*, a marker of proliferating chondrocytes, was assessed in neonatal, 15-day-old, and 8-week-old femora but was not significantly different between the 2 genotypes (Figure 2, F-H). In addition, its expression pattern in the growth plates of 15-day-old mice was indistinguishable between genotypes, as revealed by collagen 2 immunostaining (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI29463DS1). Compared with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* mice, *collagen 10* (*Col10*) mRNA level, a specific marker of hypertrophic chondrocytes, was unaltered in neonatal *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice (Figure 2F), decreased in 15-day-old mice (*P* < 0.05; Figure 2G), and at normal levels at the age of 8 weeks (Figure 2H). These data suggest that lack of VDR in chondrocytes does not manifestly impair chondrocyte development but suppresses temporarily the terminal differentiation of the chondrocytes.

*BV/TV is increased in juvenile Cre<sup>+</sup>VDR<sup>fl/fl</sup> mice.* During endochondral ossification, cartilage becomes progressively replaced by mineralized bone, which is a highly coordinated process, depending partially on factors produced by chondrocytes. To investigate the effect of VDR inactivation in chondrocytes on this process, trabec-



**Table 1**  
Bone parameters in 8-week-old mice

	<i>Cre<sup>-</sup>VDR<sup>fl/fl</sup></i>	<i>Cre<sup>+</sup>VDR<sup>fl/fl</sup></i>
Femur length (mm)	15.24 ± 0.17	14.97 ± 0.22
Trabecular BMD (mg/cm <sup>3</sup> )	119.9 ± 15.2	147.1 ± 10.8
Cortical BMD (mg/cm <sup>3</sup> )	1174 ± 5	1186 ± 6
Tibia BV/TV (%)	6.49 ± 1.59	6.05 ± 0.84
BFR/BS (μm <sup>3</sup> /μm <sup>2</sup> /day × 10 <sup>-2</sup> )	62.11 ± 6.17	67.79 ± 7.10
Growth-plate mineralization area (%)	11.78 ± 0.64	11.65 ± 0.78

BFR/BS, bone formation ratio.


ular bone parameters were quantified at several ages. At 8 weeks, static and dynamic bone parameters were normal, as evidenced by similar values between the 2 genotypes for trabecular and cortical bone mineral density (BMD) analyzed by peripheral quantitative computed tomography of the femur, BV/TV quantified on von Kossa-stained sections, and bone formation ratio (BFR/BS) assessed on unstained sections of the tibiae (Table 1).

In contrast, BV/TV was significantly increased, by 50%, in neonatal and 15-day-old *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* compared with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* mice (Figure 3A). In addition, von Kossa staining revealed that trabecular bone extended more deeply into the metaphyseal area of the proximal tibiae in 15-day-old *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice (Figure 3, B and C).


*Vascularization and osteoclast invasion are delayed when chondrocytes lack VDR.* The observed changes in bone mass in 15-day-old *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice may have resulted from increased bone formation and/or decreased bone resorption. Osteoblast function was not manifestly changed by VDR inactivation in chondrocytes, as suggested by the normal mRNA expression of the osteoblastic marker osteocalcin (Figure 3D) and runt-related transcription factor 2 (Runx2) (data not shown) in 15-day-old femora. In addition, in vitro osteogenic differentiation of bone marrow stromal cells (CFU-osteoblast) isolated from 15-day-old mice did not differ between genotypes, as comparable number and size of colonies staining positive for alkaline phosphatase or alizarin red were obtained (data not shown).

On the other hand, bone resorption may be impaired; this is often associated at these stages with changes in vascularization. These processes were investigated at E15.5 and in neonatal and 15-day-old mice. Initial blood vessel invasion in *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* tibiae, assessed by CD31 staining, was observed at E15.5, showing endothelial cells located at the bone collar/perichondrium but also invading the cartilage core (Figure 4, A and B). In contrast, in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice, endothelial cells were solely detected along the bone collar/perichondrium (Figure 4, C and D). At the same time, tartrate-resistant acid phosphatase-positive (TRAP-positive) multinuclear osteoclasts accompanying endothelial cells had just started to invade the tibial cartilage, forming the primary ossification center in *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* tibiae (Figure 4, F and G) whereas these cells were hardly observed in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* tibiae (Figure 4, H and I). Quantification revealed that blood vessel invasion in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* tibiae was only 57% of the *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* level ( $P < 0.05$ ; Figure 4E) and that the number of TRAP-positive cells even decreased, with 70% in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* tibiae compared with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* ( $P < 0.05$ ; Figure 4J).

In neonatal tibiae, the number of blood vessels invading the terminal row of the hypertrophic chondrocytes of the growth plate was reduced in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice (Figure 5B) as compared with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* mice (Figure 5A). Accordingly, intercapillary distance was significantly larger in neonatal *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* tibiae ( $P < 0.05$ ; Figure 5E). Also, in 15-day-old *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice, the intercapillary distance was significantly increased both at the terminal row of the growth plate and in the metaphysis, 150 μm distal from the hypertrophic chondrocytes (Figure 5E). The changes in vascularization were accompanied by alterations in osteoclast formation, as shown by the reduced TRAP positivity in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice (Figure 5D) compared with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* mice (Figure 5C). The number of TRAP-positive cells at the border of the growth plate was decreased by 50% in neonatal *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* tibiae (Figure 5F). This was reflected in a significant reduction of the *calcitonin receptor* mRNA level, a marker of differentiated osteoclasts, in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice (Figure 5H). Also, at 15 days, osteoclast surface in trabecular bone was decreased in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* tibiae (Figure 5G). These 2 processes, osteoclast formation and angiogenesis, are regulated by the



**Figure 2** Normal growth-plate development in chondrocyte-specific VDR-null mice. (A–D) Toluidine blue staining of the proximal tibiae from 15-day-old *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* (A and B) and *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice (C and D). Scale bar: 200 μm. (E) Quantification of the length of the hypertrophic cartilage zone in the proximal tibiae. (F–H) Gene expression of *Col2* and *Col10* in neonatal (F), 15-day-old (G), and 8-week-old (H) femora from *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* and *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice, assessed by qRT-PCR and calculated as a ratio to *HPRT* mRNA copies. \* $P < 0.05$  versus *Cre<sup>-</sup>VDR<sup>fl/fl</sup>*.

**Figure 3**


Chondrocyte-specific VDR inactivation results in increased metaphyseal bone volume in neonatal and 15-day-old mice. (A) Quantification of BV/TV in the proximal tibiae metaphysis on von Kossa–stained sections shows a significant increase in BV/TV in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice compared with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* mice. (B and C) von Kossa staining on tibiae sections of 15-day-old *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* (B) and *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice (C). Scale bar: 400  $\mu$ m. (D) *Osteocalcin* gene expression in femora (total bone or dissected diaphysis) of 15-day-old *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* and *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice was assessed by qRT-PCR analysis and calculated as a ratio to the *HPRT* mRNA copies. *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* value was set at 100%. \* $P < 0.05$ ; \*\* $P < 0.01$  versus *Cre<sup>-</sup>VDR<sup>fl/fl</sup>*.

secreted factors RANKL and VEGF, respectively. In agreement with the histological findings, mRNA expression of both factors was significantly reduced in neonatal *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* femora compared with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* mice ( $P < 0.05$ ; Figure 5H). These data indicate that vascular invasion at the growth plate and resorption of trabecular bone is decreased in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice, which can explain the observed increased bone volume.


*Chondrocytes promote osteoclastogenesis by 1,25(OH)<sub>2</sub>D<sub>3</sub>-induced RANKL expression.* Since *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice displayed retarded osteoclast invasion into cartilage and reduced *RANKL* gene expression in neonatal femora, we investigated whether 1,25(OH)<sub>2</sub>D<sub>3</sub> genomic signaling in chondrocytes regulates osteoclastogenesis, using cocultures with spleen cells. TRAP-positive multinuclear cells were formed in 1,25(OH)<sub>2</sub>D<sub>3</sub>-treated (10<sup>-8</sup> M) cocultures of calvarial-derived osteoblasts and splenocytes irrespective of the genotype (Figure 6, A and B; only results of *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* splenocytes

are shown). Under similar experimental conditions, chondrocytes isolated from *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* mice induced TRAP-positive multinuclear osteoclasts in cocultures with splenocytes from either genotype (Figure 6C). However, no osteoclasts were formed when *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* chondrocytes were used (Figure 6D). This effect was specific for the 1,25(OH)<sub>2</sub>D<sub>3</sub>/VDR signaling pathway, as prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) (10<sup>-6</sup> M) induced osteoclast formation irrespective of the chondrocyte genotype (Figure 6, E and F).

As osteoclastogenesis is dependent on the ratio of RANKL to osteoprotegerin (OPG), the mRNA level of these factors was quantified in 1,25(OH)<sub>2</sub>D<sub>3</sub>- or PGE<sub>2</sub>-treated primary cultures and compared with vehicle treatment. *RANKL* gene expression was significantly induced in osteoblasts ( $P < 0.001$ ) regardless of the genotype and stimulus (Figure 6G). In addition, 1,25(OH)<sub>2</sub>D<sub>3</sub> (10<sup>-8</sup> M) increased *RANKL* expression 30-fold in *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* chondrocytes ( $P < 0.001$ ) whereas no induction was noticed in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* chon-

**Figure 4**

Vascular invasion and osteoclast formation are impaired in E15.5 *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice. (A–D, F–I) Sets of adjacent tibial sections were immunostained for CD31 (A–D) or TRAP (F–I) to visualize endothelial cells or osteoclasts in E15.5 *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* (A, B, F, and G) and *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* (C, D, H, and I) mice, respectively. Scale bar: 200  $\mu$ m. (E) Invasion of blood vessels from the perichondrium into the cartilage core was measured and expressed relative to the cartilage width in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* and *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* tibiae. (J) Quantification of the number of osteoclasts (Oc.N) in the primary ossification center. \* $P < 0.05$  versus *Cre<sup>-</sup>VDR<sup>fl/fl</sup>*.



**Figure 5**

Decreased vascularization and osteoclast number in neonatal and 15-day-old *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice. (A–D) Endothelial cells and osteoclasts were visualized by CD31 (A and B) and TRAP (C and D) staining, respectively, in neonatal *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* (A and C) and *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* (B and D) tibiae. Scale bar: 200 µm. (E) Intercapillary distance, measured at 0, 75, and 150 µm from the growth-plate border in neonatal and 15-day-old tibiae was larger in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice compared with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* mice. (F) The number of osteoclasts at the terminal row of hypertrophic chondrocytes in neonatal tibiae was significantly lower in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice. (G) Osteoclast surface (Oc.S) was significantly decreased in 15-day-old *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* tibiae. (H) *Calcitonin receptor*, *RANKL*, and *VEGF* mRNA levels in neonatal and 15-day-old *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* femora was determined by qRT-PCR, corrected for *HPRT* mRNA copies, and expressed relative to *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* mice set at 100%. \**P* < 0.05 versus *Cre<sup>-</sup>VDR<sup>fl/fl</sup>*.

drocytes (Figure 6G). On the other hand, PGE<sub>2</sub> significantly induced *RANKL* expression in chondrocytes from either genotype (Figure 6G). *OPG* mRNA levels did not differ in any condition. Thus, these findings clearly indicate that chondrocytes can promote osteoclast differentiation by expressing *RANKL*, which is strongly induced by 1,25(OH)<sub>2</sub>D<sub>3</sub> genomic signaling.


*1,25(OH)<sub>2</sub>D<sub>3</sub> genomic signaling in chondrocytes modulates phosphaturic factor expression.* In systemic *VDR*-null mice, mineral homeostasis becomes manifestly disturbed after weaning, concurrent with the development of skeletal changes. In the present study, we investigated serum biochemistry at the age of 15 days, when endochondral ossification was clearly affected in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice. Chondrocyte-specific *VDR* inactivation did not affect calcium and parathyroid hormone (PTH) levels (Table 2). On the other hand, phosphate and 1,25(OH)<sub>2</sub>D serum concentrations were significantly increased in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice compared with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* mice (*P* < 0.05; Table 2). These changes were no longer observed in 8-week-old mice, as both serum phosphate (13.5 ± 0.6 mg/dl in *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* versus 12.9 ± 0.8 mg/dl in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>*) and 1,25(OH)<sub>2</sub>D (128 ± 13 pg/ml in *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* versus 121 ± 1 pg/ml in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>*) showed normal values.

Since phosphate homeostasis is mainly regulated by renal phosphate reabsorption, we assessed the expression of *NPT2a*, the major player in this process, expressed at the apical membrane of proximal tubular cells. Immunohistochemical staining showed more abundant *NPT2a* expression in 15-day-old *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* kidneys (Figure 7B) compared with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* kidneys (Figure 7A), which is in agreement with the increased serum phosphate level. Quantification of renal *NPT2a* mRNA level by qRT-PCR revealed a 4-fold increase in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice (*P* < 0.05; Figure 7C), confirming the immunohistochemical analysis. Concerning 1,25(OH)<sub>2</sub>D serum lev-

els, these are mainly regulated by renal *CYP27B1* expression, which hydroxylates 25-hydroxyvitamin D to its active form. In accordance with the increased 1,25(OH)<sub>2</sub>D serum levels, *CYP27B1* mRNA level was significantly increased in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* kidney (*P* < 0.01; Figure 7D) while gene expression of the catabolic enzyme *CYP24* was not changed (Figure 7E). It is noteworthy that no difference in renal *VDR* mRNA levels was observed between the 2 genotypes (Figure 7F).

These data suggest a link between the altered renal expression of these 2 genes and *VDR* inactivation in chondrocytes. A plausible factor that may affect 1,25(OH)<sub>2</sub>D as well as phosphate serum levels is *FGF23*, as *FGF23* suppresses the expression of the renal phosphate transporter *NPT2a* and of *CYP27B1* (16). In addition, bone has been identified as the largest source and regulatory site of *FGF23*, and *FGF23* expression is induced by 1,25(OH)<sub>2</sub>D<sub>3</sub> (17). Accordingly, *FGF23* mRNA level was significantly decreased in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* femora of 1-week-old and 15-day-old mice, as revealed by qRT-PCR (*P* < 0.01; Figure 7G). In addition, *FGF23* serum levels were 43% lower in 15-day-old *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice compared with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* mice (*P* < 0.01; Figure 7H). As with the age-related changes of serum phosphate and 1,25(OH)<sub>2</sub>D levels, no difference in *FGF23* serum levels was observed between the 2 genotypes in 8-week-old mice (71.4 ± 6.3 pg/ml in *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* versus 76.9 ± 12.2 pg/ml in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice). These data indicate that the increased phosphate and 1,25(OH)<sub>2</sub>D serum concentrations before weaning are likely caused by decreased *FGF23* production in bone, leading to increased renal *NPT2a* and *CYP27B1* mRNA expression.

*Genomic action of 1,25(OH)<sub>2</sub>D<sub>3</sub> in chondrocytes regulates FGF23 expression in osteoblasts in vitro.* In bone, the cells identified as producing *FGF23* are osteoblasts and osteocytes. To elucidate whether chondrocytes express *FGF23* and whether this expression is regulated by



**Figure 6** Signaling of 1,25(OH)<sub>2</sub>D<sub>3</sub> in chondrocytes promotes osteoclast differentiation by the RANKL pathway. (A–F) Microscopic observation of TRAP-positive multinuclear cells formed after 1 week of coculturing osteoblasts or chondrocytes with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* splenocytes. Osteoclast formation was similar whether osteoblasts from *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* (A) or *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice (B) were used and treated with 1,25(OH)<sub>2</sub>D<sub>3</sub> (10<sup>-8</sup> M). Chondrocytes from *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* mice induced TRAP-positive cells when stimulated with 1,25(OH)<sub>2</sub>D<sub>3</sub> (C) or 10<sup>-6</sup> M PGE<sub>2</sub> (E) whereas chondrocytes from *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice induced osteoclasts only when treated with PGE<sub>2</sub> (F) and not with 1,25(OH)<sub>2</sub>D<sub>3</sub> (D). Scale bar: 100 μm. (G) qRT-PCR analysis of *RANKL* mRNA expression in primary osteoblast or chondrocyte cultures from *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* and *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice stimulated by 10<sup>-8</sup> M 1,25(OH)<sub>2</sub>D<sub>3</sub> or 10<sup>-6</sup> M PGE<sub>2</sub> for 2 days. Values are calculated as ratio to *HPRT* mRNA copies and expressed relative to vehicle set as 100%. \**P* < 0.05; \*\**P* < 0.01 versus vehicle.

1,25(OH)<sub>2</sub>D<sub>3</sub> in vitro experiments were performed. Treatment with 1,25(OH)<sub>2</sub>D<sub>3</sub> (10<sup>-8</sup> M, 48 hours) induced *FGF23* mRNA expression 100-fold in primary osteoblasts derived from either *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* or *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* mice (Figure 8A). On the other hand, the *FGF23* message was undetectable in cultured primary chondrocytes, both in basal conditions and after 1,25(OH)<sub>2</sub>D<sub>3</sub> treatment (data not shown). These data indicate that *FGF23* expression is restricted to osteoblasts and suggest that the reduced *FGF23* expression in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice most likely results from altered expression of a chondrocyte-derived factor due to lack of VDR action. Several in vitro experiments were performed to investigate this hypothesis. First, metatarsals at E16.5, a stage when interaction between osteoblasts and chondrocytes is abundantly present, were cultured for 24 hours, after which 1 metatarsal was treated with 1,25(OH)<sub>2</sub>D<sub>3</sub> (10<sup>-8</sup> M) and the contralateral with vehicle. The relative induction of *FGF23* mRNA by 1,25(OH)<sub>2</sub>D<sub>3</sub> treatment was significantly higher in *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* than in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* metatarsals (*P* < 0.005; Figure 8B). However, the number of osteoblasts in the metatarsals may be different between the 2 genotypes, as vascular invasion and formation of the primary ossification center is delayed in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* metatarsals (Figure 4). We therefore introduced a coculture system of primary osteoblasts and chondrocytes to characterize more precisely their interaction on *FGF23* expression. Primary chondrocytes were isolated from both genotypes and cultured during 4 days, after which osteoblasts isolated from *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* calvaria were added to the culture. Treatment with 1,25(OH)<sub>2</sub>D<sub>3</sub> induced *FGF23* mRNA

expression in cocultures regardless of the presence of VDR in chondrocytes. However, the increase in *FGF23* mRNA expression by 1,25(OH)<sub>2</sub>D<sub>3</sub> treatment was significantly impaired when *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* chondrocytes were used in cocultures, as compared with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* chondrocytes (*P* < 0.001; Figure 8C), indicating that a 1,25(OH)<sub>2</sub>D<sub>3</sub>-responsive chondrocyte-derived factor contributes to *FGF23* expression in osteoblasts.

Finally, to elucidate whether *FGF23* mRNA expression in osteoblasts was modulated by a secreted factor produced by chondrocytes, a Transwell system was used with primary chondrocytes from either genotype cultured on the insert and primary osteoblasts derived from *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* calvaria on the bottom plate. No manifest differences in the growth and differentiation of osteoblasts and chondrocytes were observed between the different conditions, as *osteocalcin* expression by the osteoblasts

and *Col10* expression by the chondrocytes were comparable (data not shown). The induction of *FGF23* mRNA level by 1,25(OH)<sub>2</sub>D<sub>3</sub> was significantly higher in osteoblasts cultured with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* chondrocytes than in cultures with *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* chondrocytes (*P* < 0.001; Figure 8D). In addition, 1,25(OH)<sub>2</sub>D<sub>3</sub>-treated osteoblasts showed a more pronounced induction of *FGF23* mRNA levels when cultured with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* chondrocytes in the Transwell system than when cultured alone (compare *FGF23* mRNA level in Figure 8D with level in Figure 8A). In agreement with the results of mRNA expression, *FGF23* protein level was more increased in conditioned media from cocultures with *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* chondrocytes than from cultures with *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* chondrocytes (*P* < 0.01; Figure 8E). These results indicate that vitamin D genomic signaling in chondrocytes contributes to *FGF23* expression in osteoblasts by altering the expression of a secreted factor.

## Discussion

VDR is a 1,25(OH)<sub>2</sub>D<sub>3</sub>-regulated transcription factor required for normal mineral and skeletal homeostasis, which it contributes to mainly by regulating intestinal calcium absorption. The predominant effects of vitamin D deficiency or resistance before the end of puberty are impaired bone mineralization and abnormal growth-plate structure. Both can be corrected by a high-calcium diet. Nevertheless, a specific but possibly redundant role for VDR in bone metabolism has been suggested by in vitro data using VDR-null cells (11) and by in vivo overexpression of VDR in osteoblasts (12). To elucidate the function



**Table 2**  
Serum biochemistry in 15-day-old mice

	<i>Cre<sup>-</sup>VDR<sup>fl/fl</sup></i>	<i>Cre<sup>+</sup>VDR<sup>fl/fl</sup></i>
Calcium (mg/dl)	10.57 ± 0.08	10.77 ± 0.08
Phosphate (mg/dl)	12.87 ± 0.56	14.33 ± 0.40 <sup>A</sup>
PTH (pg/ml)	31.42 ± 2.89	37.37 ± 6.20
1,25(OH) <sub>2</sub> D (pg/ml)	74.88 ± 3.56	127.40 ± 15.86 <sup>A</sup>

<sup>A</sup>*P* < 0.05 versus *Cre<sup>-</sup>VDR<sup>fl/fl</sup>*.

of VDR during endochondral bone development, we generated mice with chondrocyte-specific inactivation of VDR. Loss of VDR in chondrocytes did not interfere with chondrocyte development but resulted unexpectedly in increased trabecular bone mass during early postnatal life due to reduced osteoclastogenesis accompanied by decreased vascularization. In addition, serum 1,25(OH)<sub>2</sub>D and phosphate levels were transiently increased in juvenile mice; this resulted from decreased FGF23 production by osteoblasts. Taken together, these data reveal what we believe to be a novel role for VDR in chondrocytes as regulators of osteoclastogenesis and controllers of phosphate homeostasis, which they achieve by affecting FGF23 production.

During endochondral bone development, chondrocytes proliferate and subsequently differentiate into hypertrophic chondrocytes that finally undergo apoptosis while being replaced by bone. Chondrocytes lacking VDR expression develop normally; this agrees with previous findings in *VDR*-null mice (3). In this latter model, the typical morphology of rickets with enlargement of the zone of hypertrophic chondrocytes mainly develops after weaning (2, 3, 7). These features can be rescued by a high-calcium/high-lactose diet, which suggests an indirect function of VDR. Recently, Sabbagh et al. (18) demonstrated that rickets is due to impaired apoptosis of the late hypertrophic chondrocytes secondary to hypophosphatemia. Consistent with this model, the length of the zone of hypertrophic chondrocytes in chondrocyte-specific *VDR*-null mice was not altered, as calcium level was normal and phosphate level was even increased. Rather, a temporary decrease in the differentiation of hypertrophic chondrocytes was observed, as *Col10* expression was reduced in 15-day-old mice. These results indicate that VDR expression in chondrocytes does not contribute to the proliferation of chondrocytes but rather minimally affects hypertrophic differentiation.


During hypertrophic differentiation, chondrocytes synthesize VEGF, a key regulator of vascular invasion, first at the primary ossification center and later at the growth plate; these are essential steps in endochondral ossification. Deficient VEGF synthesis by hypertrophic chondrocytes (19) or reduced release of VEGF from the matrix (20) due to MMP-9 inactivation results in decreased vascular invasion at the growth plate and expansion

of the hypertrophic chondrocyte layer. As a known regulator of VEGF transcription, 1,25(OH)<sub>2</sub>D<sub>3</sub> promotes vascularization at the growth plate (14). In agreement with these findings, the present results now reveal that VDR inactivation in chondrocytes results in decreased VEGF expression before weaning, associated with a reduced number of blood vessels at the border of the growth plate. Also, at the stage of primary ossification during embryonic bone development, chondrocytic *VDR*-null tibiae exhibited decreased angiogenic invasion into the cartilage anlage compared with *VDR* WT mice. However, at 8 weeks, blood vessel invasion at the growth plate was normal, suggesting that this process was rescued. This temporary phenomenon is also observed in MMP-9-null mice, in which the enlarged hypertrophic chondrocyte zone is only detected until 8 weeks (20). Taken together, these results indicate that timely *VEGF* mRNA expression by hypertrophic chondrocytes, required for vascular invasion of this zone, is partly dependent on 1,25(OH)<sub>2</sub>D<sub>3</sub> genomic action.


Concomitant with vascular invasion, the calcified matrix surrounding hypertrophic chondrocytes became degraded by chondroclasts/osteoclasts. In embryonic tibiae, the number of TRAP-positive multinuclear cells was significantly reduced when VDR expression was lacking in chondrocytes. Also, at later ages, fewer osteoclasts were detected, particularly at the border of the growth plate but also in the proximal diaphysis. These data were corroborated by decreased mRNA expression of calcitonin receptor, a specific marker for osteoclasts.

**Figure 7**

Chondrocyte-specific VDR inactivation affects phosphate–vitamin D homeostasis by decreasing FGF23 expression in bone. (A and B) Immunohistochemical staining of renal NPT2a in 15-day-old *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* (A) and *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* (B) mice. Scale bar: 50 μm. (C–G) qRT-PCR analysis of renal *NPT2a* (C), *CYP27B1* (D), *CYP24* (E), and *VDR* (F) mRNA expression in 15-day-old mice and of *FGF23* (G) mRNA expression in 1-week-old and 15-day-old femora, corrected for *HPRT* mRNA levels. *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* values are expressed relative to *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* set at 100%. (H) Serum FGF23 level was significantly decreased in 15-day-old *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice. \**P* < 0.05; \*\**P* < 0.01 versus *Cre<sup>-</sup>VDR<sup>fl/fl</sup>*.





**Figure 8**

Signaling of 1,25(OH)<sub>2</sub>D<sub>3</sub> in chondrocytes supports FGF23 expression in osteoblasts. (A–D) qRT-PCR analysis of *FGF23* mRNA expression in primary osteoblast cultures (A), in E16.5 metatarsal cultures (B), in cocultures of chondrocytes and osteoblasts (C), and in primary osteoblasts cultured in the Transwell system with chondrocytes cultured on the membrane (D), corrected for *HPRT* mRNA copies. Cultures derived from *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* or *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice were treated with 1,25(OH)<sub>2</sub>D<sub>3</sub> (10<sup>-8</sup> M) for 48 hours or vehicle. *FGF23* mRNA expression in 1,25(OH)<sub>2</sub>D<sub>3</sub>-treated metatarsals is depicted as an increase relative to its vehicle-treated contralateral (B). (E) FGF23 protein level was measured in the culture media of the Transwell system after 1,25(OH)<sub>2</sub>D<sub>3</sub> treatment. In the cocultures, only *Cre<sup>-</sup>VDR<sup>fl/fl</sup>* osteoblasts were used whereas the genotype of the chondrocytes varied as indicated. \**P* < 0.05; \*\**P* < 0.005 versus *Cre<sup>-</sup>VDR<sup>fl/fl</sup>*.

only observed in juvenile mice. This is consistent with the temporary role of the growth plate, which remains active through puberty but fuses in adult mice.

Bone metabolism and mineral homeostasis are closely interconnected and regulated mainly by the hormones 1,25(OH)<sub>2</sub>D<sub>3</sub> and PTH. As elucidated in this study, 1,25(OH)<sub>2</sub>D<sub>3</sub> genomic actions directly affect endochondral bone development by regulating specific gene expression. The 1,25(OH)<sub>2</sub>D<sub>3</sub>/VDR pathway also plays a role in mineral homeostasis, mainly by inducing intestinal and renal calcium transporter gene expression, thereby promoting calcium (re)absorption. The effect of 1,25(OH)<sub>2</sub>D<sub>3</sub> on phosphate homeostasis is, however, more complex, as it stimulates phosphate (re)absorption both directly (23) and indirectly by downregulating PTH secretion (24) while, on the other hand, it increases FGF23 secretion, thereby promoting renal phosphate excretion (16). In this latter pathway, 1,25(OH)<sub>2</sub>D<sub>3</sub> stimulates FGF23 expression in osteoblasts, which in turn decreases renal 1 $\alpha$ -hydroxylase expression and NPT2 apical localization, resulting in impaired phosphate reabsorption. This suggests that bone is involved in mineral homeostasis, which it contributes to not only by releasing calcium and phosphate but also by secreting this phosphaturic factor.

We now provide evidence that VDR action in chondrocytes contributes to this endocrine negative feedback loop between 1,25(OH)<sub>2</sub>D<sub>3</sub> and FGF23. In 15-day-old chondrocyte-specific *VDR*-null mice, serum 1,25(OH)<sub>2</sub>D and phosphate levels were significantly increased, an unexpected finding. The increased 1,25(OH)<sub>2</sub>D levels correlated with and most likely resulted from enhanced renal *CYP27B1* mRNA levels in these mice. Likewise, the increased phosphate levels can be explained by abundant NPT2a localization at the apical membrane, as shown by immunohistochemistry, and by enhanced *NPT2a* mRNA expression. In contrast, serum calcium and PTH levels were normal and therefore provide no explanation for the altered serum 1,25(OH)<sub>2</sub>D and phosphate levels. Searching for the signaling mechanism between VDR inactivation in chondrocytes and altered renal expression of *CYP27B1* and NPT2a, we investigated the expression of the major phosphatonin FGF23. *FGF23* mRNA levels were decreased in bone from chondrocyte-specific *VDR*-null mice, which explains the decreased serum FGF23 levels in these mice, as bone is the major source of circulating FGF23. This reduced FGF23 level can clarify the increased *CYP27B1* and NPT2 expression in the kidney, which in its turn results in increased 1,25(OH)<sub>2</sub>D and phosphate levels in chondrocyte-specific *VDR*-null mice. It is noteworthy that renal *CYP24* expression was not affected in chondrocyte-specific *VDR*-null mice, despite the increased serum 1,25(OH)<sub>2</sub>D level. However, FGF23 has recently been reported to

A plausible explanation for the reduced number of osteoclasts is impaired expression of RANKL, an essential factor in osteoclastogenesis. This factor is mainly produced by osteoblasts or mesenchymal cells under the control of several cytokines and hormones, including 1,25(OH)<sub>2</sub>D<sub>3</sub> (21). We identified a novel role for chondrocytes in supporting osteoclastogenesis by expressing RANKL, an effect regulated by 1,25(OH)<sub>2</sub>D<sub>3</sub> genomic action. The evidence therefore is provided by both in vivo and in vitro findings. First, *RANKL* mRNA expression was decreased in neonatal femora lacking VDR expression in chondrocytes. Second, growth-plate chondrocytes expressed RANKL in vitro, confirming a recent finding by Takamoto et al. (22). Comparable to WT osteoblasts, the mRNA expression of RANKL in WT chondrocytes was increased by 1,25(OH)<sub>2</sub>D<sub>3</sub> treatment whereas this induction was lacking in VDR-deficient chondrocytes. Third, WT chondrocytes supported osteoclastogenesis in 1,25(OH)<sub>2</sub>D<sub>3</sub>-treated cocultures with splenocytes although less efficiently than WT osteoblasts. Osteoclasts were, however, not formed when chondrocytes lacked VDR. It is noteworthy that RANKL expression and osteoclast formation were normal when *VDR*-deficient chondrocytes were stimulated with PGE<sub>2</sub>, reminiscent of the osteoblast characteristics derived from systemic *VDR*-null mice (10).

These results indicate that 1,25(OH)<sub>2</sub>D<sub>3</sub> genomic action in chondrocytes contributes to normal RANKL expression and timely osteoclast invasion in the primary ossification center and later at the border of hypertrophic chondrocytes during metaphyseal growth. The observed decrease in osteoclastogenesis in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice may also explain the increased BV/TV observed before weaning. Moreover, no changes in osteoblast parameters were noticed at these stages, as both *Runx2* and *osteocalcin* mRNA expression did not differ between genotypes. Additionally, in vitro osteogenic differentiation of bone marrow stromal cells was not altered in *Cre<sup>+</sup>VDR<sup>fl/fl</sup>* mice. The increase in bone mass was



induce CYP24 expression in the kidney (25). A plausible explanation reconciling both findings is that the decreased circulating FGF23 levels in chondrocyte-specific *VDR*-null mice neutralize the inducing effect of  $1,25(\text{OH})_2\text{D}_3$  on renal CYP24 expression.

The contribution of chondrocytes to FGF23 expression in bone is most likely indirect, as we noticed that chondrocytes do not express FGF23. The present data reveal that a soluble chondrocyte-derived factor induced by  $1,25(\text{OH})_2\text{D}_3$  genomic signaling contributes to FGF23 expression in osteoblasts. To date, the mechanism of FGF23 induction by  $1,25(\text{OH})_2\text{D}_3$  is still not fully characterized. Transcriptional regulation via *VDR* has been proposed although a VDRE has not yet been identified in the promoter region of FGF23. In addition, indirect regulation by an intermediary factor has been suggested (17, 26). We now expand this model by adding a paracrine factor secreted by chondrocytes in a  $1,25(\text{OH})_2\text{D}_3$ -dependent manner. Further investigations are necessary to identify this unknown factor.

The biological effect of *VDR* inactivation in chondrocytes is observed in early life but is transient. Indeed, the relative increase in bone mass, renal CYP27B1 expression, serum  $1,25(\text{OH})_2\text{D}_3$ , and phosphate disappeared at 8 weeks of age when the growth plate of mice became less active as the long bones nearly attained their final length.

In conclusion, the present study indicates that  $1,25(\text{OH})_2\text{D}_3$  genomic action in chondrocytes is not crucial for growth-plate development but regulates via paracrine factors bone development and phosphate homeostasis. These vitamin D-regulated genes are essential for timely vascularization and osteoclast invasion into the hypertrophic chondrocyte zone and participate in the interactive loop between FGF23 and  $1,25(\text{OH})_2\text{D}_3$ . This study also elucidates a novel function for chondrocytes as coplayers in the endocrine function of bone.

## Methods

**Animals.** Targeted mutagenesis to generate *VDR*<sup>fl/fl</sup> mice was achieved by homologous and Cre/loxP-mediated site-specific recombination in embryonic stem cells. The targeting vector consisted of cDNA containing loxP sites upstream and downstream of exon 2 (Figure 1A), as described previously (7). Chondrocyte-specific inactivation of *VDR* was obtained by crossing *VDR*<sup>fl/fl</sup> mice with transgenic mice expressing Cre recombinase under the control of Col2 gene promoter (27). After appropriate breeding, *Cre*<sup>+</sup>*VDR*<sup>fl/fl</sup> and *Cre*<sup>-</sup>*VDR*<sup>fl/fl</sup> littermates were used in the analysis. Genotyping was performed by Southern blot analysis or PCR of genomic DNA extracted from tail biopsies. All mice were bred in our animal housing facilities (Proefdierencentrum Leuven) and received normal diet containing 1.1% calcium and 0.8% phosphate (Standard; Carfil Quality-Pavan Service). These experiments were approved by the ethical committee of Katholieke Universiteit Leuven.

The age of the embryos was stated as E0.5, which was the morning a vaginal plug was observed after overnight mating. When indicated, mice received 2 intraperitoneal injections of the fluorochrome calcein (16 mg/kg; Sigma-Aldrich) 7 and 3 days before sacrifice. Blood was collected, and kidneys, intestine, and bones were dissected and processed as described (7, 28).

**Serum biochemistry.** Calcium and phosphate were analyzed by SYNCHRON Clinical System (Beckman Coulter). Levels of  $1,25(\text{OH})_2\text{D}_3$  and PTH were determined using [<sup>125</sup>I]  $1,25(\text{OH})_2\text{D}_3$  RIA kit (DiaSorin) and mouse-PTH ELISA kit (Immutopics), respectively. FGF23 protein levels in serum and cell culture media were determined using Human Intact FGF-23 ELISA kit (Kainos Laboratories Inc.) ( $n = 6$  per genotype).

**Bone length and BMD of the femur.** The left femur of 8-week-old mice ( $n = 8$  per genotype) was fixed in Burkhardt's solution. The length was measured

using a caliper (Digimatic; Mitutoyo), and BMD was assessed by quantitative computed tomography, using Stratec XCT Research M<sup>+</sup> (Norland Medical Systems Inc.) (29).

**Histology, immunohistochemistry, and histomorphometry.** Tibiae from E15.5 ( $n = 6-7$  per genotype), neonatal ( $n = 8$ ), 15-day-old ( $n = 8$ ), and 8-week-old ( $n = 8$ ) mice were analyzed. Left tibiae were fixed in Burkhardt's solution, embedded undecalcified in methyl methacrylate, and sectioned at 10  $\mu\text{m}$ . Right tibiae were fixed in 2% paraformaldehyde, decalcified in 0.5 M EDTA (pH 7.4)/PBS prior to dehydration, embedded in paraffin, and sectioned at 5  $\mu\text{m}$ .

For general morphological analysis, decalcified sections were stained with Harris H&E or with 2% toluidine blue. Methyl methacrylate sections were stained according to the von Kossa method to assess mineralized bone. Osteoclasts were visualized on paraffin sections reacted for TRAP activity (28). Additional sections were used for CD31 and collagen 2 staining as previously described (28, 30). Histomorphometric analysis was done as previously described (28, 29), using a Kontron Elektronik image-analyzing system (KS 400 V 3.00; Zeiss). Dynamic bone parameters were calculated using formulas described previously (31).

Kidneys were incubated overnight in 30% sucrose after fixation in 4% paraformaldehyde for 2 hours, embedded in Shandon Cryomatrix (Thermo Electron Corp.), and sectioned at 5  $\mu\text{m}$ . Immunohistochemical staining for NPT2a was performed with rabbit anti-NPT2a in 1:400 dilutions (32) followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin (EnVision system; Dako). Harris H&E was used for counterstaining.

**Primary osteoblast, chondrocyte, and bone marrow stromal cell cultures and cocultures.** Primary growth-plate chondrocytes were isolated from proximal tibiae and distal femora of 3-day-old mice by 0.2% collagenase-A digestion (30). From the same mice, primary osteoblasts were isolated from calvaria by sequential digestion with 0.1% collagenase A and 0.2% dispase. Osteoblastic cells from the second to fifth fraction were pooled (33). Cells were cultured for 4 days (40,000 cells/cm<sup>2</sup>), then treated with  $10^{-8}$  M and  $10^{-10}$  M  $1,25(\text{OH})_2\text{D}_3$  (a kind gift from J.P. Vandeveldel, Solvay, Weesp, The Netherlands),  $10^{-6}$  M PGE<sub>2</sub>, (Sigma-Aldrich), or vehicle for another 2 or 3 days, whereafter cells were harvested for RNA isolation. Bone marrow stromal cells isolated from 15-day-old femora were cultured according to the method described previously (34). To assess CFU osteoblast, cells were cultured in 6-well plates (52,000 cells/cm<sup>2</sup>) for 10 days and 21 days, whereafter they were stained for alkaline phosphatase or with alizarin red, respectively (34).

The regulation of FGF23 expression was studied in cocultures of primary osteoblasts and chondrocytes. Two types of coculture were used: either the 2 cell types were cultured adjacent to each other or they were cultured separated by a membrane. In the first condition, *Cre*<sup>-</sup>*VDR*<sup>fl/fl</sup> or *Cre*<sup>+</sup>*VDR*<sup>fl/fl</sup> chondrocytes were cultured in 12-well plates (40,000 cells/cm<sup>2</sup>) in DMEM/F12 (1:1) (Invitrogen) supplemented with 10% FCS, 50  $\mu\text{g}/\text{ml}$  ascorbic acid, and 100  $\mu\text{g}/\text{ml}$  sodium pyruvate for 4 days, whereafter primary *Cre*<sup>-</sup>*VDR*<sup>fl/fl</sup> osteoblasts (40,000 cells/cm<sup>2</sup>) were added. In the second setup, the same cell types were used, but chondrocytes were cultured on BD Falcon cell culture insert (16,000 cells/cm<sup>2</sup>; pore size 0.4  $\mu\text{m}$ ), and after 4 days, osteoblasts were seeded in the lower well. After 2 days, cocultures were treated with  $10^{-8}$  M  $1,25(\text{OH})_2\text{D}_3$  for 48 hours. All quantifications were performed on 4 wells per group and repeated 2 to 4 times.

**In vitro osteoclast differentiation.** Osteoclast formation was studied in cocultures of primary osteoblasts or chondrocytes and spleen cells using all 4 combinations of genotypes. Osteoblasts (23,000 cells/cm<sup>2</sup>) or chondrocytes (45,000 cells/cm<sup>2</sup>) were cultured in 8-well chamber slides (Lab-Tek II; Nunc) in  $\alpha$ -MEM/10% FCS for 6 hours, whereafter spleen cells (230,000 cells/cm<sup>2</sup>) were added. Cultures were treated with  $10^{-8}$  M  $1,25(\text{OH})_2\text{D}_3$  or  $10^{-6}$  M PGE<sub>2</sub> for 7 days, with medium and factors replaced



every 2 days. At the end of the culture period, cells were stained for TRAP (33). TRAP-positive multinuclear cells containing more than 3 nuclei were identified as osteoclasts.

**Metatarsal cultures.** Right and left metatarsals were dissected from E16.5 embryos ( $n = 6$  per genotype), stripped of skin and surrounding tissues, and cultured on a BD Falcon insert membrane (pore size,  $0.4 \mu\text{m}$ ) in 12-well plates in BGJb medium (Invitrogen) supplemented with  $0.1\%$  BSA,  $25 \mu\text{g/ml}$  ascorbic acid, and  $10 \text{ mM}$   $\beta$ -glycerophosphate. After 24 hours, the right metatarsal was treated with  $10^{-8} \text{ M}$   $1,25(\text{OH})_2\text{D}_3$  and the contralateral with vehicle for 2 days, whereafter RNA was isolated.

**Isolation of RNA and qRT-PCR.** Total RNA from neonatal, 1-week-old, 15-day-old, and 8-week-old mice ( $n = 8$  per group), of kidneys from 15-day-old mice ( $n = 8$  per group), and of cultured metatarsals was extracted with TRIzol (Invitrogen). RNA from cultured chondrocytes or osteoblasts was isolated using TRIzol LS (Invitrogen) or RNeasy Mini Kit (QIAGEN). Subsequently, cDNA was synthesized using reverse transcriptase SuperScript II RT (Invitrogen). Real-time qRT-PCR was performed on an ABI Prism 7700 Sequence Detector (Applied Biosystems). Specific forward and reverse oligonucleotide primers and probes with fluorescent dye (FAM) and quencher (TAMRA) were used for *calcitonin receptor*, *Col2*, *Col10*, *CYP24*, *CYP27B1*, *FGF23*, *OPG*, *osteocalcin*, *RANKL*, *Rumx2*, *VEGF*, and *VDR*. Expression levels were normalized for *hypoxanthine-guanine phosphoribosyl transferase (HPRT)* expression

(Supplemental Table 1). *NPT2a* mRNA expression was analyzed by TaqMan Gene Expression Assays (ID Mm00441450 m1; Applied Biosystems).

**Statistics.** Results are expressed as the mean  $\pm$  SEM. To assess the effect of genotype or treatment, data were compared by 2-tailed Student's *t* test or Mann-Whitney *U* test after *F* test using StatView (SAS) software.  $P < 0.05$  was considered significant.

## Acknowledgments

We are grateful to R. Behringer for providing Col2a1 Cre mice, to J. Biber for providing NPT2a antiserum, and to N. Smets, I. Jans, K. Moerman, and A. Vanden Bosch for technical help. This work was supported by a grant from the Fund for Scientific Research-Flanders (FWO; G. 0508.05). C. Maes is a postdoctoral fellow from FWO (Belgium).

Received for publication June 21, 2006, and accepted in revised form September 19, 2006.

Address correspondence to: Geert Carmeliet, Laboratory of Experimental Medicine and Endocrinology, O & N, Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. Phone: 32-16-34-5974; Fax: 32-16-34-5934; E-mail: geert.carmeliet@med.kuleuven.be.

- Hausler, M.R., et al. 1998. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. *J. Bone Miner. Res.* **13**:325–349.
- Yoshizawa, T., et al. 1997. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. *Nat. Genet.* **16**:391–396.
- Li, Y.C., et al. 1997. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. *Proc. Natl. Acad. Sci. U. S. A.* **94**:9831–9835.
- Kitanaka, S., et al. 1998. Inactivating mutations in the 25-hydroxyvitamin D<sub>3</sub> 1 $\alpha$ -hydroxylase gene in patients with pseudovitamin D-deficiency rickets. *N. Engl. J. Med.* **338**:653–661.
- Panda, D.K., et al. 2001. Targeted ablation of the 25-hydroxyvitamin D 1 $\alpha$ -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. *Proc. Natl. Acad. Sci. U. S. A.* **98**:7498–7503.
- Dardenne, O., Prud'homme, J., Arabian, A., Glorieux, F.H., and St-Arnaud, R. 2001. Targeted inactivation of the 25-hydroxyvitamin D<sub>3</sub>-1 $\alpha$ -hydroxylase gene (*CYP27B1*) creates an animal model of pseudovitamin D-deficiency rickets. *Endocrinology*. **142**:3135–3141.
- Van Cromphaut, S.J., et al. 2001. Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. *Proc. Natl. Acad. Sci. U. S. A.* **98**:13324–13329.
- Balsan, S., et al. 1986. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D. *J. Clin. Invest.* **77**:1661–1667.
- Amling, M., et al. 1999. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. *Endocrinology*. **140**:4982–4987.
- Takeda, S., et al. 1999. Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. *Endocrinology*. **140**:1005–1008.
- Sooy, K., Sabbagh, Y., and Demay, M.B. 2005. Osteoblasts lacking the vitamin D receptor display enhanced osteogenic potential in vitro. *J. Cell. Biochem.* **94**:81–87.
- Gardiner, E.M., et al. 2000. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. *FASEB J.* **14**:1908–1916.
- Karsenty, G., and Wagner, E.F. 2002. Reaching a genetic and molecular understanding of skeletal development. *Dev. Cell.* **2**:389–406.
- Lin, R., et al. 2002. 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> promotes vascularization of the chondro-osseous junction by stimulating expression of vascular endothelial growth factor and matrix metalloproteinase 9. *J. Bone Miner. Res.* **17**:1604–1612.
- Mirams, M., Robinson, B.G., Mason, R.S., and Nelson, A.E. 2004. Bone as a source of FGF23: regulation by phosphate? *Bone*. **35**:1192–1199.
- Saito, H., et al. 2003. Human fibroblast growth factor-23 mutants suppress Na<sup>+</sup>-dependent phosphate co-transport activity and 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> production. *J. Biol. Chem.* **278**:2206–2211.
- Kolek, O.I., et al. 2005. 1 $\alpha$ ,25-Dihydroxyvitamin D<sub>3</sub> upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. *Am. J. Physiol. Gastrointest. Liver Physiol.* **289**:G1036–G1042.
- Sabbagh, Y., Carpenter, T.O., and Demay, M.B. 2005. Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. *Proc. Natl. Acad. Sci. U. S. A.* **102**:9637–9642.
- Haigh, J.J., Gerber, H.P., Ferrara, N., and Wagner, E.F. 2000. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. *Development*. **127**:1445–1453.
- Vu, T.H., et al. 1998. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. *Cell*. **93**:411–422.
- Yasuda, H., et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc. Natl. Acad. Sci. U. S. A.* **95**:3597–3602.
- Takamoto, M., et al. 2003. Hedgehog signaling enhances core-binding factor a1 and receptor activator of nuclear factor-kappaB ligand (RANKL) gene expression in chondrocytes. *J. Endocrinol.* **177**:413–421.
- Yamamoto, H., et al. 2005. Alternative promoters and renal cell-specific regulation of the mouse type Iia sodium-dependent phosphate cotransporter gene. *Biochim. Biophys. Acta.* **1732**:43–52.
- Zhao, N., and Tenenhouse, H.S. 2000. Npt2 gene disruption confers resistance to the inhibitory action of parathyroid hormone on renal sodium-phosphate cotransport. *Endocrinology*. **141**:2159–2165.
- Inoue, Y., et al. 2005. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. *Biochem. J.* **390**:325–331.
- Ito, M., et al. 2005. Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. *Am. J. Physiol. Endocrinol. Metab.* **288**:E1101–E1109.
- Ovchinnikov, D.A., Deng, J.M., Ogunrinu, G., and Behringer, R.R. 2000. Col2a1-directed expression of Cre recombinase in differentiating chondrocytes in transgenic mice. *Genesis*. **26**:145–146.
- Maes, C., et al. 2002. Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF<sub>164</sub> and VEGF<sub>188</sub>. *Mech. Dev.* **111**:61–73.
- Daci, E., Verstuyf, A., Moermans, K., Bouillon, R., and Carmeliet, G. 2000. Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency. *J. Bone Miner. Res.* **15**:1510–1516.
- Maes, C., et al. 2004. Soluble VEGF isoforms are essential for establishing epiphyseal vascularization and regulating chondrocyte development and survival. *J. Clin. Invest.* **113**:188–199. doi:10.1172/JCI200419383.
- Masuyama, R., et al. 2003. Dietary calcium and phosphorus ratio regulates bone mineralization and turnover in vitamin D receptor knockout mice by affecting intestinal calcium and phosphorus absorption. *J. Bone Miner. Res.* **18**:1217–1226.
- Custer, M., Lotscher, M., Biber, J., Murer, H., and Kaissling, B. 1994. Expression of Na-P(i) cotransport in rat kidney: localization by RT-PCR and immunohistochemistry. *Am. J. Physiol.* **266**:F767–F774.
- Daci, E., Udagawa, N., Martin, T.J., Bouillon, R., and Carmeliet, G. 1999. The role of the plasminogen system in bone resorption in vitro. *J. Bone Miner. Res.* **14**:946–952.
- Miyamoto, K., et al. 2003. Prostaglandin E<sub>2</sub>-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture. *J. Bone Miner. Res.* **18**:1471–1477.